Ubs Group Ag Nuvectis Pharma, Inc. Call Options Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NVCT
# of Institutions
32Shares Held
1.65MCall Options Held
0Put Options Held
0-
Ronit Capital LLP563KShares$2.87 Million5.37% of portfolio
-
Vanguard Group Inc Valley Forge, PA301KShares$1.54 Million0.0% of portfolio
-
Baldwin Brothers LLC174KShares$888,0620.08% of portfolio
-
Black Rock Inc. New York, NY83.4KShares$425,4010.0% of portfolio
-
Geode Capital Management, LLC Boston, MA79.7KShares$406,5510.0% of portfolio
About Nuvectis Pharma, Inc.
- Ticker NVCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 14,642,500
- Market Cap $74.7M
- Description
- Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src...